ArticleCancer research communications2026
Pseudogene Coexpression Networks Reveal a Robust Prognostic Signature for Pediatric B-ALL Survival.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Risk classification in B-cell acute lymphoblastic leukemia (B-ALL) remains challenging, even in the era of genomic precision medicine. Current molecular classifiers fail to fully explain the heterogeneity in patient outcomes, suggesting that key regulatory layers remain hidden. In this study, we uncover a previously unexplored dimension of B-ALL biology by analyzing coexpression patterns between pseudogenes using single-sample coexpression networks (n = 1,416). Principal component analysis showed that these interactions explain a major component of variability among patients and contribute to patient stratification into clusters with distinct overall survival. After identifying interactions associated with these clusters, we used a LASSO-based feature selection pipeline to derive a three-interaction signature that predicted patient survival, with RPL7P10-RPS3AP36 emerging as the most robust biomarker. Our study shows that coexpression between pseudogenes represents a previously unrecognized layer of molecular heterogeneity in B-ALL, harboring promising molecular markers for future studies. SIGNIFICANCE: This study reveals pseudogene coexpression as a previously unrecognized driver of transcriptional heterogeneity in B-ALL. We identify robust survival biomarkers derived from these interactions and introduce a single-sample network framework that enables precise patient stratification and biomarker validation in independent cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.